PURPOSE: Aims of the study are to narrow-down the hotspot region on 10q21 defined by previous genome-wide loss of heterozygosity (LOH) analysis in head and neck squamous cell carcinomas (HNSCC) and to define candidate tumor suppressor genes (TSG) concerned with 10q21. MATERIALS AND METHODS: LOH analysis was carried out with ten polymorphic microsatellite markers. Expression analysis was performed by semi-quantitative RT-PCR, and mutation analysis by PCR and direct sequencing. RESULTS: LOH analysis on 10q21 in 52 HNSCC indicated distinctive and frequent allelic loss at D10S589 (42%). Among flanking genes, we found the RHOBTB1 gene as a candidate TSG, since an intragenic marker demonstrated the highest LOH (44%). Expression analysis revealed down-regulation of RHOBTB1 mRNA in 37% of tumors. Interestingly, all the five tumors that showed decreased expression of RHOBTB1 were accompanied with LOH, supporting the haploinsufficiency and class 2 TSG characteristics of RHOBTB1. No pathogenic mutation of RHOBTB1 was found. Furthermore, another gene within the region, EGR2, was also taken under scope. LOH frequencies around the EGR2 gene were relatively low (23 and 33%). Albeit semi-quantitative expression analysis of EGR2 demonstrated downregulation in 45% of tumor samples, no relation was found between the expression levels and LOH status. CONCLUSION: Frequent allelic loss and decreased expression of RHOBTB1 suggested that this gene has a role in tumorigenesis of a subset of HNSCC.
PURPOSE: Aims of the study are to narrow-down the hotspot region on 10q21 defined by previous genome-wide loss of heterozygosity (LOH) analysis in head and neck squamous cell carcinomas (HNSCC) and to define candidate tumor suppressor genes (TSG) concerned with 10q21. MATERIALS AND METHODS: LOH analysis was carried out with ten polymorphic microsatellite markers. Expression analysis was performed by semi-quantitative RT-PCR, and mutation analysis by PCR and direct sequencing. RESULTS: LOH analysis on 10q21 in 52 HNSCC indicated distinctive and frequent allelic loss at D10S589 (42%). Among flanking genes, we found the RHOBTB1 gene as a candidate TSG, since an intragenic marker demonstrated the highest LOH (44%). Expression analysis revealed down-regulation of RHOBTB1 mRNA in 37% of tumors. Interestingly, all the five tumors that showed decreased expression of RHOBTB1 were accompanied with LOH, supporting the haploinsufficiency and class 2 TSG characteristics of RHOBTB1. No pathogenic mutation of RHOBTB1 was found. Furthermore, another gene within the region, EGR2, was also taken under scope. LOH frequencies around the EGR2 gene were relatively low (23 and 33%). Albeit semi-quantitative expression analysis of EGR2 demonstrated downregulation in 45% of tumor samples, no relation was found between the expression levels and LOH status. CONCLUSION: Frequent allelic loss and decreased expression of RHOBTB1 suggested that this gene has a role in tumorigenesis of a subset of HNSCC.
Authors: B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: D Gasparotto; T Vukosavljevic; S Piccinin; L Barzan; S Sulfaro; M Armellin; M Boiocchi; R Maestro Journal: Int J Cancer Date: 1999-08-20 Impact factor: 7.396
Authors: M Srivastava; L Bubendorf; V Srikantan; L Fossom; L Nolan; M Glasman; X Leighton; W Fehrle; S Pittaluga; M Raffeld; P Koivisto; N Willi; T C Gasser; J Kononen; G Sauter; O P Kallioniemi; S Srivastava; H B Pollard Journal: Proc Natl Acad Sci U S A Date: 2001-04-03 Impact factor: 11.205
Authors: Sunita Gupta; Mai X Luong; Sylvia A Bleuming; Angela Miele; Michael Luong; Daniel Young; Erik S Knudsen; Andre J Van Wijnen; Janet L Stein; Gary S Stein Journal: J Cell Physiol Date: 2003-09 Impact factor: 6.384
Authors: Silvia S Borkosky; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Esra Gunduz; Mahmoud A L Sheikh Ali; Andrea P Rodriguez; Mehmet Zeynel Cilek; Susumu Tominaga; Noboru Yamanaka; Kenji Shimizu; Noriyuki Nagai Journal: J Cancer Res Clin Oncol Date: 2008-11-08 Impact factor: 4.553
Authors: Masashi Mukohda; Shi Fang; Jing Wu; Larry N Agbor; Anand R Nair; Stella-Rita C Ibeawuchi; Chunyan Hu; Xuebo Liu; Ko-Ting Lu; Deng-Fu Guo; Deborah R Davis; Henry L Keen; Frederick W Quelle; Curt D Sigmund Journal: J Clin Invest Date: 2019-03-21 Impact factor: 14.808
Authors: Hansjuerg Alder; Cristian Taccioli; Hongping Chen; Yubao Jiang; Karl J Smalley; Paolo Fadda; Hatice G Ozer; Kay Huebner; John L Farber; Carlo M Croce; Louise Y Y Fong Journal: Carcinogenesis Date: 2012-06-10 Impact factor: 4.944
Authors: Christopher J Pelham; Pimonrat Ketsawatsomkron; Séverine Groh; Justin L Grobe; Willem J de Lange; Stella-Rita C Ibeawuchi; Henry L Keen; Eric T Weatherford; Frank M Faraci; Curt D Sigmund Journal: Cell Metab Date: 2012-10-03 Impact factor: 27.287